SEC Form 4 · accession 0001179022-17-000079
GALECTIN THERAPEUTICS INC · GALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Kevin D Freeman
Director
Period of report
Dec 14, 2017
Accepted (ET)
Dec 18, 2017 · 4:12 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001133416
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock option (right to buy)F1 | $2.39 | Dec 14, 2017 | A | 46,875 | A | — | Dec 14, 2027 | Common stock | 46,875 | 46,875 | D |
Explanation of responses
- F1The options vest 100% on December 14, 2018.